Clinical Trials Logo
  1. Home
  2. Hyperhidrosis
  3. NCT02563899

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

Hyperhidrosis Clinical Trial

Official title:
A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects With Primary Axillary Hyperhidrosis

Clinical Trial Summary

This is a double blind (sponsor unblind), repeat dose, randomized, parallel group, placebo controlled study to assess the pharmacokinetic parameters, safety, tolerability, and clinical effect of topically applied umeclidinium following once daily topical administration to axilla for 14 days in subjects with primary axillary hyperhidrosis. This study will determine whether topically applied umeclidinium can decrease hyperhidrosis without systemic anticholinergic effects (ie. in the range or lower to those obtained after inhaled route) at the highest possible concentration.

Subjects will be dosed by site staff each night immediately before bedtime for 14 days. Subjects will complete gravimetric and Hyperhidrosis Disease Severity Scale (HDSS) measurements, patient reported outcomes (PRO), safety assessments, and/or pharmacokinetic sampling. Follow up visits will occur on days 15, 16, 19, 23 and 28. The total duration of the study will be approximately 6 to 8 weeks. The study is planned to enroll approximately 24 subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02563899
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date November 23, 2015
Completion date February 25, 2016
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04924036 - Qbrexza Cloths for Hyperhidrosis of Amputation Sites Phase 2
Recruiting NCT04178161 - Image Guided Targeted Photoablation for the Treatment of Localized Hyperhidrosis N/A
Completed NCT02565732 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis Phase 2
Completed NCT02552199 - A Non-Interventional Study To Assess Sweating
Recruiting NCT01930604 - Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis Phase 2
Completed NCT01811004 - Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis N/A
Completed NCT01671800 - Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating Phase 1
Completed NCT01956591 - Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis N/A
Completed NCT01934153 - Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects Phase 1
Completed NCT06113978 - Thoracoscopic Sympathetic Chain Interruption for Palmar Hyperhidrosis in Patients Below 18 N/A
Not yet recruiting NCT05102396 - Topical Oxybutynin for Treatment of Hyperidrosis: a Local or a Systemic Effect? Phase 2
Completed NCT04906655 - An Open Label Study for Palmar Hyperhydrosis Phase 2
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Withdrawn NCT05546710 - miraDry Post Market Tumescent Anesthesia Study N/A
Completed NCT02016885 - A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis Phase 2
Completed NCT00168480 - A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase 4
Completed NCT03416348 - Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2 Phase 1
Completed NCT02973659 - The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar. N/A
Not yet recruiting NCT05805696 - Treatment and Mapping of Impostor Phenomenon N/A
Completed NCT03816046 - Hyperhydrosis Treatment Using Botulinum Toxin Phase 4